The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 8805 participants.
Also called NCT06494878
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 8,805 participants
- Registry
-
NCT06494878
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium, Canada, Denmark, France, Ireland, Netherlands, Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT06494878. Randomized; no masking; primary purpose prevention. Start 2026-06-04 (actual); primary completion 2030-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
- Condition
- Venous Thromboembolism
- Condition
- Postpartum Period
- Condition
- Aspirin
- Condition
- Low Molecular Weight Heparin
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Low-molecular-weight heparin
- Lead sponsor
- University of Calgary
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- European Clinical Research Infrastructure Network
Record details
- Record id
cardio:ct-nct06494878- Content hash
5cda8c95dba6ca223dea2088e9ba62645fa370df32fea45a57b241dd9a3692c1